Table 1 Subjects' clinical characteristics at baseline.
| Â | Placebo (25) | Raloxifene (50) | Tamoxifen (50) |
|---|---|---|---|
Age (Lower-upper quartile) | 44 (42-47) | 46 (42-49) | 45 (41-49) |
Age at menarche (Lower-upper quartile) | 13 (12-13) | 12 (12-13) | 12 (11-14) |
Parity | 1 | 2 | 2 |
Family history1 BC°- OC°° | 5 - 1 | 15 - 1 | 11 - 3 |
Body mass index (Lower-upper quartile) | 22.9 (21.7-26.2) | 22.2 (20.5-24.6) | 22.2 (20.3-25.2) |
Smoking Never/former/current/ missing | 14/3/8/0 | 28/10/11/1 | 24/5/21/0 |
Tumor size mm (Lower-upper quartile) | 22.0 (15-30) | 22.5 (15.0-28.5) | 21.5 (15.0-27.5) |
Tumor grade 1/2/3/unknown2 | 7/7/5/6 | 3/23/7/17 | 3/22/8/17 |
HER2 overexpression % No/yes | 96/4 | 98/2 | 94/6 |
Luminal subtype % A/B HER2 neg/B HER2 pos | 36/60/4 | 20/78/2 | 27/67/3 |